Next-Generation Sequencing
The latest news on next-generation sequencing.
Foundation Medicine Test Approved by FDA as CDx for Itovebi in Breast Cancer Patients
The test is approved for patients with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.
Velsera, Diagnóstica Longwood Partner for Precision Genomics Medicine in Spain, Portugal
The collaboration will bring together Velsera's clinical genomics analysis software with Diagnóstica Longwood's regional distribution knowledge and network.
The firm last week announced it received funding that will allow it to complete development of the test, called Myelo-Scan, by the end of 2026.
Tempus, Takeda Expand Collaboration to Use Multimodal Data for Oncology R&D
Takeda will use Tempus' multimodal datasets and biological modeling capabilities in its cancer therapeutic development work.
Massive Bio, Foundation Medicine Partner to Improve Oncology Clinical Trial Enrollment
The companies will develop integrated solutions that use shared data and AI analytics focused on patient matching to clinical trials.